CRISPR BY DESIGN

Serial Number 90596751
606

Registration Progress

Application Filed
Mar 23, 2021
Under Examination
Aug 16, 2022
Approved for Publication
Jun 21, 2022
Published for Opposition
Jun 21, 2022
Registered

Trademark Image

CRISPR BY DESIGN

Basic Information

Serial Number
90596751
Filing Date
March 23, 2021
Published for Opposition
June 21, 2022
Abandonment Date
September 22, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Sep 22, 2025
Classes
005 044

Rights Holder

Scribe Therapeutics Inc.

03
Address
1150 Marina Village Parkway
Alameda, CA 94501

Ownership History

Scribe Therapeutics Inc.

Original Applicant
03
Alameda, CA

Scribe Therapeutics Inc.

Owner at Publication
03
Alameda, CA

Legal Representation

Attorney
John Paul Oleksiuk

USPTO Deadlines

All Deadlines Cleared

All 4 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

43 events
Date Code Type Description Documents
Sep 22, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Sep 22, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jan 29, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 28, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Jan 22, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Jan 22, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 16, 2024 NOAC E CORRECTED NOA E-MAILED Loading...
Dec 16, 2024 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Dec 16, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 16, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Nov 22, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Nov 18, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Oct 23, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Aug 19, 2024 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Aug 19, 2024 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Aug 14, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 14, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Feb 9, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 8, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 8, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 8, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Aug 12, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 10, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 10, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Aug 10, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 10, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 8, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 8, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 8, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 16, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 21, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 21, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 1, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 26, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 26, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 26, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 28, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Oct 28, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 28, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 27, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 28, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 26, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeuticsin the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders
Class 044
Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions

Classification

International Classes
005 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CRISPR"